AN2 Therapeutics (ANTX) CEO receives new stock options and RSUs

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. director and Chief Executive Officer Eric Easom reported new equity awards. He received a stock option for 224,500 shares at an exercise price of $0.0000 per share and a grant of 112,250 shares of Common Stock on February 20, 2026.

The 112,250-share grant represents restricted stock units that vest in 25% increments annually over four years from January 1, 2026, subject to continuous service. The option vests 1/48 of the shares monthly over four years from January 1, 2026. Easom also reports indirect ownership of Common Stock through the Easom Living Trust and two irrevocable trusts.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Easom Eric

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	224,500	$0.00	--
Grant/Award	Common Stock	112,250	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 224,500 shares (Direct); Common Stock — 368,630 shares (Direct); Common Stock — 1,065,766 shares (Indirect, See Footnote)

Footnotes (1)

1. Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Includes a balance of (i) 145,250 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025 and (ii) 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019. Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021. Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Easom Eric

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		A		112,250(1)	A	$0	368,630(2)	D
Common Stock								1,065,766	I	See Footnote(3)
Common Stock								97,058	I	See Footnote(4)
Common Stock								97,058	I	See Footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.04	02/20/2026		A		224,500		(6)	02/19/2036	Common Stock	224,500	$0	224,500	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

2. Includes a balance of (i) 145,250 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025 and (ii) 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date.

3. Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.

4. Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.

5. Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.

6. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Lucy Day, Attorney-in-Fact for Eric Easom	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did AN2 Therapeutics (ANTX) CEO Eric Easom receive?

Eric Easom received a stock option for 224,500 shares and a grant of 112,250 shares of Common Stock. Both were awarded on February 20, 2026 as part of his equity compensation, with vesting tied to continued service over four years.

How do the new AN2 Therapeutics CEO RSUs and options vest?

The 112,250 restricted stock units vest 25% annually over four years starting January 1, 2026. The 224,500-share stock option vests monthly, with 1/48 of the shares vesting each month over four years from January 1, 2026.

What is the exercise price of Eric Easom’s new AN2 Therapeutics stock option?

The new stock option granted to Eric Easom covers 224,500 shares at an exercise price of $0.0000 per share. This effectively makes it a no-cost option to acquire shares as they vest, subject to his continued service with the company.

Does the AN2 Therapeutics CEO have indirect ownership through trusts?

Yes. The Form 4 reports indirect ownership of Common Stock through the Easom Living Trust dated August 21, 2019 and two irrevocable trusts dated October 8, 2021. These trust holdings are separate from Easom’s directly held and newly granted equity awards.

Are Eric Easom’s AN2 Therapeutics equity grants contingent on continued service?

Yes. Both the RSUs and the option vest only if Eric Easom maintains continuous service. RSUs vest annually, and the option vests monthly, all starting from January 1, 2026, making ongoing employment a condition for earning the full equity benefit.

What does transaction code A mean in the AN2 Therapeutics Form 4?

Transaction code A indicates a grant, award, or other acquisition of securities rather than an open-market purchase or sale. For Eric Easom, this code applies to the 224,500-share option and the 112,250-share Common Stock grant awarded as part of his compensation.